The company remains entirely pre-revenue, with quarterly SG&A expenses rising from $123.7K in 2023Q3 to $1.6M by 2025Q3, reflecting significant fixed-cost burdens.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 7.18M | 5.54M | 631.32K | 574.37K | 1.11M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 6.67M | 5.54M | 631.32K | 574.37K | 1.11M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 509.85K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.18M | -5.54M | -631.32K | -574.37K | -1.11M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -777.56% | -9.91% | 48.21% | - |
| EBITDA | -7.5M | -5.79M | -631.24K | -574.23K | -1.11M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -81.47% | -817.83% | -9.93% | 48.22% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 |
| EBIT | -7.5M | -5.79M | -631.24K | -574.23K | -1.11M |
| Net Interest Income | -3.79M | -356.6K | -76.21K | -24.37K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.79M | 356.6K | 76.21K | 24.37K | 0 |
| Other Income/Expense | -4.11M | -610.14K | -76.14K | -24.22K | 44 |
| Pretax Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | -168.2% | -769.36% | -18.19% | 46.03% | - |
| Net Income (Continuing) | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19 | -0.32 | -0.04 | -0.03 | -0.06 |
| EPS Growth % | 8.11% | -769.57% | -18.33% | 46.01% | - |
| EPS (Basic) | - | -0.32 | -0.04 | -0.03 | -0.06 |
| Diluted Shares Outstanding | 59.42M | 19.25M | 19.25M | 19.25M | 19.25M |
| Basic Shares Outstanding | 59.42M | 19.25M | 19.25M | 19.25M | 19.25M |
| Dividend Payout Ratio | - | - | - | - | - |
Imminent liquidity and dilution
As indicated by recent financial disclosures, Klotho Neurosciences has seen its quarterly SG&A expenses climb from $123.7K in 2023Q3 to $1.6M by 2025Q3, reflecting the significant operational burden of maintaining a public entity without any corresponding revenue generation to offset these rising fixed costs.
The company's cost structure is currently dominated by administrative overhead, which has expanded significantly following the transition to a public entity. This trend suggests that management is prioritizing corporate infrastructure over clinical development, which warrants further investigation into the efficiency of these expenditures given the company's extremely limited cash position.
According to the provided income statement data, Klotho Neurosciences recorded significant stock-based compensation charges, including a peak of $2.0M in 2024Q3, which complicates the assessment of true cash burn and suggests that equity-based incentives are being used to preserve limited liquid capital reserves.
The reliance on non-cash compensation appears to be a strategic attempt to manage cash outflows, yet it creates volatility in net income figures that may obscure the underlying operational burn rate. Investors should monitor whether this reliance on equity incentives continues as the company approaches critical clinical milestones.
Based on reported filings, Klotho Neurosciences remains entirely pre-revenue, with no product sales or licensing income recorded over the last ten quarters, confirming that the firm is currently in a capital-intensive phase focused exclusively on preclinical research and development of its Klotho protein platform.
The absence of top-line growth suggests that the company's valuation is driven entirely by speculative clinical potential rather than fundamental performance. This binary business model implies that any future revenue will likely be lumpy and milestone-dependent, rather than indicative of a stable or recurring commercial trajectory.
As reported in financial statements, the company's cash balance of $63,741 as of the most recent period suggests a precarious financial position that may necessitate immediate dilutive financing to sustain ongoing research activities and cover the recurring quarterly operating losses of approximately $1.9 million.
The current cash-to-burn ratio appears unsustainable, indicating that the company may face a liquidity crisis in the near term. This vulnerability suggests that shareholders should prepare for significant dilution, as the firm lacks the internal cash generation required to fund its pipeline through to human clinical trials.
Quick answers to the most common questions about buying KLTOW stock.
For fiscal year 2024, Klotho Neurosciences, Inc. (KLTOW) reported total revenue of $0.0M.
Klotho Neurosciences, Inc. (KLTOW) reported a net loss of $6.2M for the fiscal year ending 2024.